Rheumatoid arthritis (RA)
Conditions
Interventions
Osteoarthritis (OA) patient group:None
Rheumatoid arthritis (RA) patient group:None
Sponsors
The First Affiliated Hospital of Wenzhou Medical University
Eligibility
Sex/Gender
All
Age
18 Years to 75 Years
Inclusion criteria
Inclusion criteria: Healthy Control Group (Normal Subjects) : 1.Aged 18–65 years, regardless of gender;no personal or family history of joint-related hereditary diseases; 2.No joint swelling, pain or limited mobility upon physical examination,no abnormalities in joint imaging examinations (X-ray/ultrasound). 3.No administration of anti-inflammatory drugs, immunosuppressants or glucocorticoids, and no joint-related treatment received within the recent 3 months; 4.Hepatic and renal function, routine blood indicators, as well as inflammatory markers (ESR, CRP) are all within the normal reference range. Osteoarthritis (OA) : 1. Aged 40–75 years, regardless of gender;meeting the diagnostic criteria for knee osteoarthritis specified in the Guidelines for the Diagnosis and Treatment of Osteoarthritis (2021 Edition). 2.Clinical manifestations include knee pain, joint stiffness (morning stiffness duration = 30 minutes), accompanied by possible joint deformity and functional limitation,patients with knee joint involvement are preferentially enrolled. 3.Laboratory examinations may present positive rheumatoid factor (RF), positive anti-cyclic citrullinated peptide antibody (anti-CCP antibody), and elevated inflammatory indicators (ESR, CRP).
Exclusion criteria
Exclusion criteria: Healthy Control Group 1.With a previous or current diagnosis of rheumatoid arthritis, osteoarthritis, gouty arthritis, or any other joint diseases; 2.Suffering from systemic diseases such as autoimmune diseases, infectious diseases, malignant tumors, and hepatic or renal insufficiency; 3.Having a history of trauma or surgery within the last 3 months, or taking medications that affect inflammatory responses and immune function. Osteoarthritis (OA) : 1.Combined with other joint diseases (e.g., rheumatoid arthritis, gouty arthritis, ankylosing spondylitis) or autoimmune diseases; 2.With secondary joint lesions including joint infection, tuberculosis, tumor, traumatic fracture, joint dislocation, or having a history of joint revision surgery; 3.Receiving intra-articular injection drugs (e.g., glucocorticoids, sodium hyaluronate), oral hormone drugs or immunosuppressant therapy within the last 1 month; 4.Suffering from severe hepatic and renal insufficiency, malignant tumors, coagulation disorders, or infectious diseases. Rheumatoid Arthritis (RA) 1.Combined with other joint diseases such as osteoarthritis, gouty arthritis and ankylosing spondylitis, or severe infection, tuberculosis and malignant tumors; 2.With joint trauma, fracture, dislocation, infection or a history of joint revision surgery, which may interfere with sample collection and result evaluation; 3.Receiving standardized treatment with biological agents, glucocorticoids, immunosuppressants or intra-articular drug injection within the last 1 month; 4.Suffering from severe hepatic and renal insufficiency, coagulation disorders, or cardiovascular diseases.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Expression levels of CCL18 and CDC42EP2 in synovial tissues; | — |
Secondary
| Measure | Time frame |
|---|---|
| Clinical disease activity indices (DAS28-ESR/CRP, CDAI, SDAI); | — |
Countries
China
Contacts
Public ContactChen Lv
The First Affiliated Hospital of Wenzhou Medical University
Outcome results
None listed